News Sentiment

WVE sentiment intelligence

Wave Life Sciences Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.82 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-6.9% over one week, -5.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -6.9% Price reacting lower
Trend fit Trend inactive -5.5% over four weeks
Fair value -26.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 36
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 21
TradingView 9
Stock Titan 5
simplywall.st 4
Sahm 3
Simply Wall Street 2
Quartr 2
Moomoo 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 19
Regulatory and legal 4
Analyst action 3
Balance sheet 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Simply Wall Street Direct company coverage

Is Wave Life Sciences (WVE) Undervalued Or Is Its RNA Pipeline Already Priced In?

Wave Life Sciences (WVE) has seen recent share price fluctuations, with a weak short-term trend but strong long-term returns. Investors are divided, with one narrative suggesting the stock is undervalued at $22.19 based on its RNA pipeline and upcoming clinical data, while anothe

Tone
Neutral 50/100
Event
Market update
Published
22 Jul 2026 02:39
Source
Simply Wall Street
TipRanks Direct company coverage

Wave Life Sciences Pte. Ltd (WVE) Q1 2025 Earnings Report - Results, Call & Slides

Wave Life Sciences (WVE) released its Q1 2025 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -$0.29 against a consensus of -$0.26 and actual revenue of $9.18 million compared to an expected $11.92 million. The revenue marked a si

Tone
Negative 36/100
Event
Earnings
Published
19 Jul 2026 07:39
Source
TipRanks
TradingView Direct company coverage

ETFs Investing in Wave Life Sciences Ltd. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Wave Life Sciences Ltd. (1U5) stocks, providing financial details for each fund. The ETFs cover different investment styles and sectors, including small-cap, health care, and biotechnology, offering diverse investm

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 01:41
Source
TradingView
Intellectia AI Direct company coverage

WVE Financials: Revenue Breakdown, Margins & Competitor Comparison

WAVE Life Sciences Ltd (WVE) exhibits a remarkable 100.00% gross margin, indicating strong pricing power and manufacturing efficiency. Despite this, the company faces challenges with negative operating and net margins, at -81.83% and -68.21% respectively, alongside a Return on Eq

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 00:13
Source
Intellectia AI
Sahm Direct company coverage

Has Wave Life Sciences (WVE) Fallen Far Enough To Look Fairly Valued?

Wave Life Sciences (WVE) stock has dropped significantly in 2026, yet still appears expensive when evaluated using traditional metrics, particularly its Price-to-Sales (P/S) ratio of 16.7x compared to an industry average of 6.7x. Despite recent progress in its RNA programs, the c

Tone
Negative 30/100
Event
Market update
Published
11 Jul 2026 00:10
Source
Sahm
Quartr Direct company coverage

Wave Life Sciences (WVE) 44th Annual J.P. Morgan Healthcare Conference Summary

Wave Life Sciences (WVE) presented at the 44th Annual J.P. Morgan Healthcare Conference, outlining its strategic vision to leverage RNA medicines with proprietary chemistry and deep genetic insights. The company is well-capitalized with a cash runway into Q3 2028 and is focusing

Tone
Positive 74/100
Event
Balance sheet
Published
09 Jul 2026 00:40
Source
Quartr
Quartr Direct company coverage

Wave Life Sciences (WVE) Jefferies London Healthcare Conference 2025 Summary

Wave Life Sciences (WVE) presented a summary of their Jefferies London Healthcare Conference 2025, highlighting their focus on an integrated RNA medicines platform for genetic diseases. Key updates included the Inhibin E program (WVE-007) for obesity, showing promising preclinica

Tone
Positive 73/100
Event
Market update
Published
08 Jul 2026 23:42
Source
Quartr
Moomoo Direct company coverage

Press Release: Wave Life Sciences Announces Singapore Court Hearing, to Be Held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

Wave Life Sciences has announced that the Singapore Court will hold a hearing on July 14, 2026, to approve its scheme of arrangement for redomiciliation. This move is part of the company's strategic efforts to change its domicile. The hearing is a crucial step in the redomiciliat

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 12:09
Source
Moomoo
Market source Direct company coverage

Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

Wave Life Sciences has announced that the Singapore Court will hold a hearing on July 14, 2026, to approve its Scheme of Arrangement for redomiciliation to the United States. The company previously obtained shareholder approval for this move, which involves a statutory procedure

Tone
Neutral 50/100
Event
Regulatory and legal
Published
07 Jul 2026 22:50
Source
Market source
Investing.com Direct company coverage

Wave Life Sciences court hearing set for July 14 on redomiciliation

Wave Life Sciences has scheduled a court hearing in Singapore for July 14, 2026, to seek approval for its redomiciliation to the United States. The biotechnology company, which has seen stock volatility recently, holds more cash than debt and is attracting positive analyst rating

Tone
Neutral 50/100
Event
Analyst action
Published
07 Jul 2026 21:09
Source
Investing.com
Stock Titan Direct company coverage

Wave Life faces July 14 Singapore court hearing on U.S. redomicile

Wave Life Sciences has obtained shareholder approval for its redomiciliation to the United States and is awaiting a Singapore High Court hearing on July 14, 2026, to approve the scheme of arrangement. The company has filed the necessary application, and the court has set deadline

Tone
Positive 70/100
Event
Regulatory and legal
Published
07 Jul 2026 20:41
Source
Stock Titan
Sahm Direct company coverage

Wave Life Sciences (WVE) Is Up 7.4% After Advancing RNA-Based Obesity Drug Into Phase 2a Trial

Wave Life Sciences (WVE) saw its stock rise by 7.4% after moving its RNA-based obesity drug, WVE-007, into a Phase 2a trial. This advancement follows promising Phase 1 data showing reductions in waist circumference, visceral fat, and total fat. The drug, a GalNAc-siRNA monotherap

Tone
Positive 66/100
Event
Market update
Published
05 Jul 2026 22:50
Source
Sahm
Simply Wall Street Direct company coverage

Is Wave Life Sciences (WVE) Undervalued On Its New Obesity Trial Progress?

Wave Life Sciences (WVE) has initiated the Phase 2a multidose part of its INLIGHT trial for obesity drug candidate WVE-007, following positive Phase 1 data. Despite recent share price weakness, analysts consider the stock undervalued with a fair value of $22.19 against its curren

Tone
Positive 66/100
Event
Market update
Published
02 Jul 2026 20:39
Source
Simply Wall Street
Market source Direct company coverage

Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?

Wave Life Sciences (WVE) stock has gained 2.1% in the past four weeks, with Wall Street analysts projecting a potential upside of 294.7% based on a mean target price of $22.93. While price targets are cautioned as potentially misleading, a positive trend in earnings estimate revi

Tone
Positive 74/100
Event
Earnings
Published
01 Jul 2026 14:10
Source
Market source
Market source Direct company coverage

Wave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM Trial

Wave Life Sciences (WVE) has initiated the multidose Phase 2a of its INLIGHT trial to evaluate WVE-007, an experimental GalNAc-siRNA, as a monotherapy for obesity with comorbidities. This follows promising results from the Phase 1 single-dose component, which showed clinically si

Tone
Positive 74/100
Event
Earnings
Published
30 Jun 2026 16:34
Source
Market source
TradingView Direct company coverage

Price to earnings forward of Wave Life Sciences Ltd. – NASDAQ:WVE

This article provides limited financial information for Wave Life Sciences Ltd. (NASDAQ: WVE), specifically mentioning its "Price to earnings forward." The content is part of a TradingView page, indicating it's likely a data point rather than an in-depth analysis. Most of the pro

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 04:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Wave Life Sciences Ltd. – NASDAQ:WVE

The article focuses on the enterprise value to EBIT forward for Wave Life Sciences Ltd. (NASDAQ: WVE). It is a financial data point presented within the TradingView platform, showing that for the reported period, the value is listed as "No trades." The page provides financial ove

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 20:10
Source
TradingView
Sahm Direct company coverage

Does Wave Life Sciences’ (WVE) RNA Obesity Program Signal a Shift in Its Competitive Positioning?

Wave Life Sciences has advanced its investigational RNA therapy, WVE-007, into Phase 2a for obesity, with plans to combine it with incretins and use it as a post-incretin maintenance approach. This move, alongside the RestorAATion 2 data for WVE-006, is seen as crucial for the co

Tone
Neutral 50/100
Event
Regulatory and legal
Published
27 Jun 2026 19:40
Source
Sahm
TradingView Direct company coverage

Price to sales forward of Wave Life Sciences Ltd. – NASDAQ:WVE

This page from TradingView displays the "Price to sales forward" for Wave Life Sciences Ltd. (NASDAQ: WVE). It indicates that the market is currently closed, and no trades have occurred for this specific metric. The content emphasizes that the data is provided by various financia

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 19:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Wave Life Sciences Ltd. – NASDAQ:WVE

This article provides a financial metric for Wave Life Sciences Ltd. (NASDAQ: WVE), specifically its enterprise value to EBITDA forward. It indicates a period value and details regarding changes in this metric, noting that the content is provided by various financial data service

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 15:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Wave Life Sciences Ltd. – NASDAQ:WVE

This article focuses on the enterprise value to revenue forward of Wave Life Sciences Ltd. (NASDAQ:WVE). It provides a brief mention of this financial metric within the context of the company's financial overview on TradingView. The article itself is very sparse and primarily con

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 04:09
Source
TradingView
TradingView Direct company coverage

Wave Life Sciences Ltd. Actuals & Estimates (NASDAQ:WVE)

This article provides an overview of Wave Life Sciences Ltd. (NASDAQ:WVE) stock, including its current price, market capitalization, and historical performance. It also details actual and estimated financial data, analyst forecasts for future price targets, and upcoming earnings

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 18:10
Source
TradingView
Stock Titan Direct company coverage

Wave Life Sciences (WVE) shareholders approve Singapore Scheme for redomiciliation

Wave Life Sciences Ltd. shareholders have approved a court-supervised Scheme of Arrangement for redomiciliation to Singapore. All 87 Scheme Shareholders voted in favor, representing 155,190,836 shares. The company will now apply to the Singapore High Court for final approval, exp

Tone
Positive 71/100
Event
Regulatory and legal
Published
26 Jun 2026 12:40
Source
Stock Titan
Moomoo Direct company coverage

We Think Wave Life Sciences (NASDAQ:WVE) Can Afford To Drive Business Growth

This article analyzes Wave Life Sciences' financial position, noting its significant cash reserves of US$177m and minimal debt. It suggests the company has sufficient capital to fund its operations for over two years, indicating a strong ability to invest in and grow its business

Tone
Positive 71/100
Event
Balance sheet
Published
26 Jun 2026 12:09
Source
Moomoo